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Abstract: Anti-tumor necrosis factor therapy with adalimumab is an effective therapy for the 
induction and maintenance of remission in moderate to severe Crohn’s disease. Although a 
large proportion of patients show a favorable clinical response to adalimumab, therapy failure 
is common. In this review, we provide a practical overview of adalimumab therapy in patients 
with Crohn’s disease, with a specific focus on the clinical management of adalimumab failure. 
In the case of inadequate efficacy, a thorough assessment is required to confirm inflammatory 
disease activity and rule out noninflammatory causes. Evaluation may include biomarkers 
(fecal calprotectin and serum C-reactive protein), colonoscopy, and/or magnetic resonance 
enterography/enteroclysis. Furthermore, adalimumab trough levels and antibodies to adalimumab 
are informational after the confirmation of active inflammation. In the case of low or undetect-
able adalimumab trough levels, dose escalation to 40 mg weekly is recommended, whereas 
high antibody titers or adverse events frequently require switching to an alternative anti-TNF 
agent such as infliximab. Active inflammation despite therapeutic adalimumab trough levels 
requires alternative strategies such as switching to drugs with a different mode of action or 
surgical intervention.
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Introduction
When treating patients with Crohn’s disease, therapy is generally aimed at successful 
induction and subsequent maintenance of remission, as well as reducing therapy-
related complications, avoidance of (prolonged) glucocorticosteroid administration, 
and improved quality of life. Mucosal healing and histological normalization of the 
inflamed intestinal mucosa is another therapeutic endpoint, as evidence suggests that 
mucosal healing may have a beneficial effect on the disease course.1
Anti-tumor necrosis factor (TNF) therapy is an effective therapy for Crohn’s 
disease, and a large proportion of patients show a favorable response to these 
therapeutic antibodies. The first patients with Crohn’s disease were successfully 
treated in 1995 with anti-TNF therapy.2 The development and subsequent introduc-
tion in clinical practice of the anti-TNF agents infliximab (which received US Food 
and Drug Administration [FDA] approval in 1998) and adalimumab (which received 
FDA approval in 2007) has led to an important broadening of the therapeutic arsenal 
for treating Crohn’s disease patients. Despite therapeutic efficacy of anti-TNF agents, 
treatment failure is commonly observed, and in recent years, significant progress has 
been made in optimizing the clinical management of loss of response to these agents. 
In this review, we provide a practical overview of adalimumab therapy in Crohn’s 
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disease patients, with a specific focus on the clinical manage-
ment of adalimumab failure.
Pharmacology of adalimumab
Adalimumab is a fully humanized, recombinant, monoclonal 
immunoglobulin G1 antibody that targets TNF. Adalimumab 
binds with high affinity and specificity to TNF, leading to 
inhibition of the interaction between TNF and its cell sur-
face TNF receptor, thereby neutralizing the inflammatory 
effects of TNF. After a single subcutaneous administration 
of 40 mg adalimumab in healthy volunteers, the maximal 
serum  concentration was observed after approximately 
5 days. The average absolute bioavailability of adalimumab 
was 64%, and the mean terminal half-life is approximately 
14 days.3 The mean serum concentration of adalimumab 
after the induction phase (160 mg at week 0 followed 
by 80 mg at week 2) was approximately 13 µg/mL.4 In 
patients with rheumatoid arthritis, adalimumab levels are 
influenced by concomitant methotrexate administration, as 
those patients receiving combination therapy display higher 
median adalimumab concentrations.5 However, concomi-
tant therapy with thiopurines did not lead to an important 
alteration in adalimumab serum concentrations in Crohn’s 
disease patients.4 Conversely, adalimumab therapy also has 
no influence on thiopurine metabolism, as demonstrated 
by a prospective pharmacokinetic study in 12 patients with 
Crohn’s disease.6
As adalimumab is a humanized therapeutic protein, anti-
bodies against adalimumab may be generated over time. In 
general, the presence of these antidrug  antibodies has been 
associated with an increased risk for adverse events and 
reduced therapeutic efficacy as, for example, demonstrated for 
infliximab.7 There is evidence to suggest that administration 
of adalimumab leads to a lower rate of  anti-drug-antibody for-
mation compared with the chimeric monoclonal antibody 
infliximab. In the Clinical Assessment of Adalimumab Safety 
and Efficacy Studied as an Induction Therapy in Crohn’s II 
(CLASSIC II) trial, investigating the efficacy and safety of 
maintenance adalimumab therapy in comparison with pla-
cebo, only 2.6% (n=7) of patients developed antibodies 
against adalimumab. Interestingly, two of these seven patients 
(29%) who had detectable  anti-adalimumab antibodies in 
this trial were in clinical remission at week 56.8 In a single-
center study from  Leuven, Belgium, that investigated the 
efficacy of adalimumab therapy after previous infliximab 
failure,  discontinuation of adalimumab was related to low 
adalimumab trough levels;9 in addition, low adalimumab 
trough levels were more often detected in patients with 
detectable antibodies against adalimumab.9 The potential 
clinical significance of the pharmacokinetics of adalimumab 
trough levels and antidrug antibodies has been underlined 
by a cross-sectional study in 40 Crohn’s disease patients that 
investigated mucosal  healing outcomes during adalimumab 
therapy.10 Adalimumab trough levels were significantly higher 
in patients who were in clinical remission and in those show-
ing mucosal healing at endoscopy. Moreover, the  presence of 
antibodies against adalimumab was predictive of not achieving 
mucosal healing at endoscopy.10
Clinical evidence  
of adalimumab efficacy
Several large, randomized controlled trials have been  crucial 
for establishing the efficacy of adalimumab therapy in 
Crohn’s disease for both induction as well as maintenance 
of remission. These trials provide insight into adalimumab 
failure and its management and will be briefly summarized 
for this purpose.
The CLASSIC I trial was designed as a Phase III, 
 dose-ranging induction trial for adalimumab in moderate to 
severe Crohn’s disease.4 In this randomized, double-blind, 
placebo-controlled trial, 299 anti-TNF-naïve subjects were 
randomized to receive adalimumab (weeks 0 and 2) at 
160/80 mg, 80/40 mg, 40/20 mg, or placebo. After 4 weeks, 
remission rates (Crohn’s Disease Activity Index [CDAI] 
score, ,150 points, primary endpoint) were 36%, 24%, 18%, 
and 12% for 160/80 mg, 80/40 mg, 40/20 mg, and placebo, 
respectively. The highest-dosing groups combined (160/80 
and 80/40 mg) showed statistical significance (P=0.004) 
compared with placebo. Differences in remission rates 
were greater in adalimumab-treated patients versus placebo 
when C-reactive protein (CRP) level is 1 mg/dL or higher 
compared with the subgroup with CRP levels lower than 
1.0 mg/dL. Mean serum concentrations of adalimumab were 
12.61±5.25, 5.65±3.06, and 2.79±1.48 µg/mL for the 160/80 
mg, 80/40 mg, and 40/20 mg groups, respectively.
Subsequently, in a small, Phase II maintenance study 
(the CLASSIC II trial), all patients from the CLASSIC I 
trial who achieved and maintained remission with open-label 
adalimumab 40 mg every other week (eow) for an additional 
4 weeks (n=55) were re-randomized to receive adalimumab 
40 mg eow, 40 mg weekly, or placebo for 56 weeks.11 Patients 
not in remission at either time entered the open-label phase 
and received adalimumab 40 mg eow (n=204). The primary 
endpoint was maintenance of clinical remission (defined as 
CDAI,150 points) in randomized patients through week 56. 
At week 56, clinical remission rates were 79%, 83%, and 
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44% for the 40 mg eow, 40 mg weekly, and placebo groups, 
respectively. Of the remaining 204 patients who entered 
the open-label cohort, 131 patients completed the 56-week 
treatment protocol. Remission and response rates (clinical 
response was defined as a decrease in CDAI of at least 100 
points) at week 56 in the open-label cohort were 46% and 
65%. The small patient number (n=18–19) in the randomized 
group, as well as the lack of a placebo group in the open-
label cohort, limited the ability to draw firm conclusions 
from this trial.
Therefore, a larger Phase III, randomized, double-blind, 
placebo-controlled study was conducted to investigate the 
efficacy of adalimumab maintenance therapy in patients 
with moderate to severe Crohn’s disease (the Crohn’s Trial 
of the Fully Human Antibody Adalimumab for Remission 
 Maintenance [CHARM]).12 Patients received adalimumab 
induction therapy (80/40 mg) at weeks 0 and 2 and were 
 subsequently randomized to receive 40 mg eow, 40 mg 
weekly, or placebo through week 56. The primary endpoint 
was the rate of randomized responders (defined as CDAI 
decrease $70 points at week 4) who achieved clinical 
remission (CDAI,150 points) at weeks 26 and 56. At base-
line, 49.6% of enrolled subjects had a history of  anti-TNF 
exposure. Among the randomized responders (499; 58%), 
remission rates were 40%, 47%, and 17% at week 26 and 
36%, 41%, and 12% at week 56 for adalimumab 40 mg 
eow, 40 mg weekly, and placebo, respectively (P,0.001 for 
each dose versus placebo). Remission rates were higher in 
anti-TNF-naïve patients compared with anti-TNF exposed 
subjects: 42% (40 mg eow) and 48% (40 mg weekly) of 
patients in the anti-TNF-naïve group were in clinical remis-
sion at week 56 versus 31% (40 mg eow) and 34% (40 mg 
weekly) in the anti-TNF-experienced group. In an open-label 
extension study of CHARM, called the Additional Long-
Term Dosing with Humira to Evaluate Sustained Remission 
and Efficacy in Crohn’s Disease trial (ADHERE trial), the 
effect of 2-year adalimumab maintenance therapy on fistula 
healing was studied.13 Significant and complete healing of 
draining fistulas was observed in adalimumab-treated patients 
(59.5% [22/37]), and long-term healing of draining fistulas 
was maintained over the course of 2 years. The concomitant 
usage of antibiotics had no additional effect on the healing 
of fistulas in this study. However, a Dutch randomized and 
placebo-controlled trial comparing the efficacy of combina-
tion therapy of adalimumab and ciprofloxacin (12 weeks) 
with adalimumab alone in treating perianal fistulas showed 
that the combination was more effective (clinical response, 
71% versus 47%).14 Of note, after cessation of ciprofloxacin, 
the beneficial effect of the initial coadministration was not 
maintained over time.
In the Gauging Adalimumab Efficacy in Infliximab 
Nonresponders (GAIN) trial, eff icacy of adalimumab 
induction therapy in patients with prior infliximab failure 
was investigated.8 In this 4-week randomized, double-blind, 
 placebo-controlled trial, patients were eligible in case of 
moderate to severe Crohn’s disease and disease activity 
despite infliximab treatment or intolerance to infliximab. 
Patients were randomly assigned to either adalimumab 160/80 
mg at weeks 0 and 2 or placebo. The primary endpoint was 
induction of clinical remission (CDAI,150 points). A total of 
325 subjects were randomized, and at week 4, clinical remis-
sion and response (CDAI decrease .70 points) rates were 
21% and 52% (adalimumab) versus 7% and 34%  (placebo), 
respectively. When remission rates in the  adalimumab 
group were stratified according to loss of response (20%) or 
intolerance to infliximab (22%), or to the presence (22%) or 
absence (22%) of anti-infliximab antibodies, no significant 
differences were observed. We can deduce from this landmark 
study that patients who previously responded to infliximab 
but discontinued this therapy may benefit from a switch to 
adalimumab irrespective of the underlying reason for ces-
sation of infliximab.
Dosing of adalimumab therapy
The greatest remission rates with adalimumab have been 
achieved with initiation of a loading dose of 160/80 mg. As 
outlined earlier, the CLASSIC I trial showed remission rates 
at week 4 of 36% with the 160/80 mg induction regimen and 
24% for the 80/40 mg induction in anti-TNF-naïve patients.4 
In patients who were previously treated with infliximab, 
remission rates with the 160/80 mg induction dosing were 
greater compared with those for placebo (21% versus 7%; 
P,0.001).8
The standard maintenance dosage of adalimumab is 
40 mg eow, which is largely based on the outcomes of the 
CHARM study, demonstrating no significant differences 
between 40 mg weekly and eow at week 56.12
Primary nonresponse  
to adalimumab
Definition and incidence
Patients who do not respond to adalimumab induction 
therapy with a reduction in clinical signs and symptoms 
are considered primary nonresponders.15 In general, rates 
of primary nonresponse are variable because of differences 
in trial methods and cohorts but also because of a lack of 
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uniform definitions. Factors such as timing of assessment 
after induction therapy as well as definition of clinical 
response vary greatly among clinical trials and explain, 
at least in part, the range of reported primary nonresponse 
rates.16 In larger controlled clinical trials such as CLASSIC I, 
CHARM, and GAIN, approximately 40% of patients were 
considered primary nonresponders.4,8,12 In uncontrolled series 
evaluating anti-TNF therapy, primary nonresponse rates tend 
to be lower.17 For example, primary nonresponse, defined 
as discontinuation of adalimumab and already assessed at 
week 4 of the induction scheme, was approximately 30% 
in an observational cohort of Crohn’s disease patients who 
failed infliximab.9
Causes and risk factors for primary 
nonresponse
Several mechanisms underlying primary nonresponse to 
anti-TNF therapy have been proposed. The inflammatory 
mechanism can be mediated by other inflammatory cascades 
than TNF. This, in turn, can be dependent on, for example, 
the genetic background of the patient or a later disease phase. 
Support for the latter hypothesis comes from the observation 
that a shorter duration of disease is associated with higher 
response rates to anti-TNF therapy.16,18 In the CHARM trial, 
remission rates were approximately 60% in patients who had 
Crohn’s disease for less than 2 years compared with 40% 
(P,0.05) in patients who had a longer duration of disease.12 
Pharmacokinetic factors such as drug elimination, drug 
 binding, and antidrug antibodies may play a role as well in 
the mechanism of primary nonresponse.
Risk factors for primary nonresponse include the small 
bowel extent of disease, smoking, longer disease duration, 
and normal CRP levels.16,18 Although genetic risk factors have 
been proposed, the evidence is currently insufficient to be of 
relevance in clinical practice.18 Most studies that addressed 
risk factors for primary nonresponse assessed the response 
to infliximab, and studies in adalimumab nonresponders are 
required to improve our understanding in this matter.
Management
Prolonged administration of adalimumab beyond the 
 proposed induction phase of 4 weeks may be applied in 
patients who do not have a clinical effect after the loading 
dose of 160/80 mg. Indeed, initial nonresponders in the 
CHARM study showed an increase in clinical remission 
rates when adalimumab was continued (26% by week 8 
and 28% by week 12).12 There is no solid evidence that 
continuation of adalimumab eow for a period longer than 
12 weeks is of benefit in patients who do not demonstrate 
any clinical response.
If clinical response remains absent despite adequate 
adalimumab induction therapy, persistent disease activity 
should be confirmed. Clinical symptoms at baseline are 
frequently the result of noninflammatory causes in which 
case anti-TNF therapy is unlikely to provide clinical benefit. 
Recommendations for the diagnostic evaluation are discussed 
in the next sections. After confirmation of disease activity, 
a switch in therapeutic strategy will usually be required. 
Traditionally, primary nonresponse to anti-TNF therapy is 
considered a class effect with poor benefit from switching 
within the same drug class. Thus, switching to a different 
class of drugs, such as other immunosuppressives or integ-
rin inhibitors such as natalizumab and vedolizumab,19,20 is 
considered appropriate. However, recent reports showed, in 
small cohorts, clinical benefit in some patients who switched 
to adalimumab after primary nonresponse to infliximab,21,22 
but no evidence is yet available that supports the switch to 
infliximab for primary nonresponders to adalimumab. In a 
small series of 7 Crohn’s disease patients with only partial 
response to adalimumab and subsequent discontinuation, 
none showed benefit from switching to infliximab.23
Secondary nonresponse  
to adalimumab
Definition and incidence  
of secondary nonresponse
After successful induction of remission after adalimumab 
therapy, recurrence of symptoms can occur (so-called 
secondary nonresponse). This phenomenon also suffers 
from a lack of clear definition, but in general, secondary 
nonresponse implies recurrence of inflammatory disease 
activity. Most controlled trials define clinical remission 
as CDAI lower than 150 points and clinical response as 
a reduction in CDAI of 70 points or more from baseline. 
Thus, not achieving these goals 6–12 weeks after the start 
of induction therapy with initial response is a more specific 
definition of secondary nonresponse.17 Noninflammatory 
symptoms mimicking relapse of disease activity can 
negatively affect secondary nonresponse rates. Suspected 
secondary nonresponse is, especially in less recent studies, 
not always endoscopically confirmed. In daily practice, 
adalimumab dose escalation is a practical surrogate marker 
for secondary nonresponse. Despite variations in definitions, 
approximately 40% of initial responders to anti-TNF therapy 
lose response over time.12,24,25 For adalimumab, reported 
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secondary nonresponse rates in controlled clinical trials 
range from 21% to 46%.8,12
Evaluation of secondary nonresponse
Traditionally, clinical symptoms such as abdominal pain 
or diarrhea were used to guide the therapeutic decision-
making process. Initial trials that evaluated efficacy of 
adalimumab therapy, such as CLASSIC I, CLASSIC II, 
and CHARM, used a CDAI score lower than 150 points 
to define remission.4,11,12 However, multiple studies have 
underlined the poor correlation between clinical symptoms 
and inflammatory burden. For example, endoscopic disease 
activity showed a relatively good correlation with serum 
(CRP) and fecal (calprotectin, lactoferrin) biomarkers, but 
not with CDAI in Crohn’s disease patients.26 Furthermore, 
other conditions such as irritable bowel syndrome and bile 
acid malabsorption can mimic Crohn’s disease symptoms in 
the absence of inflammation. Thus, more objective measures 
of disease activity are required if loss of response to anti-TNF 
agents is suspected.
Serum CRP is an accurate marker of inflammation 
and correlates well with disease activity and relapses in 
Crohn’s disease.27 Furthermore, an elevated CRP serum 
level 12 weeks after the start of adalimumab treatment was 
associated with a poor response to therapy and predicted 
absence of mucosal healing in Crohn’s disease patients.28 
A second biomarker that is frequently used to assess disease 
activity despite adalimumab therapy is fecal calprotectin. 
This noninvasive biomarker of mucosal inflammation may 
accurately predict a relapse of Crohn’s disease.29 An elevated 
calprotectin level after adalimumab induction therapy also 
predicted the absence of clinical remission at 12 months. It 
was shown that only 38% of inflammatory bowel disease 
patients with an elevated calprotectin level after adalimumab 
induction therapy achieved clinical remission at 12 months, 
in contrast to 84% achieving clinical remission after normal-
ization of calprotectin levels.30
Infectious causes of diarrhea should be ruled out before 
further analysis. If stool analyses reveal pathogens, antibiotic 
therapy should be initiated accordingly. Infectious episodes 
and antibiotics can trigger relapses of Crohn’s disease, and in 
the case of persistent symptoms, further diagnostic work-up 
should be considered.
Despite the accuracy of biomarkers, such as CRP and fecal 
calprotectin, to predict Crohn’s disease activity, a colonos-
copy remains the gold standard for diagnostic  evaluation. 
Endoscopic evaluation can assess mucosal inflammation and 
allows for mucosal biopsies. A  colonoscopy can also identify 
complications of Crohn’s disease, such as strictures that can 
cause symptoms in the absence of inflammation. Additional 
imaging should be considered in the case of incomplete 
endoscopic assessment, the suspicion of proximal small 
bowel disease, or discrepancies between biomarkers and 
colonoscopy. Magnetic resonance enterography or enterocly-
sis is the preferred imaging method that can identify active 
inflammation as well as complications of the disease, such 
as fistulas, abscesses, or stenosis.
If diagnostic evaluation does not identify inflammation, 
a relapse of Crohn’s disease is unlikely, and alternative 
causes should be considered. Common causes that can mimic 
Crohn’s disease activity include irritable bowel syndrome 
and bile salt malabsorption, but other explanations can be 
considered as well on an individual basis, such as lactose 
intolerance, small bowel bacterial overgrowth, and celiac 
disease. Alternatively, noninflammatory complications of 
Crohn’s disease can be diagnosed by endoscopy or imaging. 
For example, a stricture can cause obstructive symptoms, and 
in this case, escalation of medical therapy is unlikely to result 
in clinical improvement, especially when a fibrotic stricture 
is present without active inflammation.
If ongoing intestinal inflammation is confirmed and 
infections are ruled out, therapeutic management requires 
optimization. Trough levels and antibodies to adalimumab 
can guide this process (Figure 1). The timing for measuring 
trough levels and antidrug antibodies is variable. In the case 
of a high likelihood of disease activity, measurement can take 
place during the ongoing diagnostic evaluation to accelerate 
therapeutic optimization. If the likelihood of inflammatory 
disease activity is low, measurement can also be scheduled, 
depending on diagnostic outcomes. There is currently no 
evidence available to support routine measurements when 
patients maintain a state of clinical remission.
Several studies explored the use of trough levels and anti-
bodies to predict clinical outcomes with infliximab therapy. 
For example, in the Study of Immunomodulator Naïve Patients 
in Crohn’s Disease (SONIC trial), Crohn’s disease patients 
with infliximab and trough levels higher than 1 µg/mL had 
a higher chance of achieving steroid-free clinical remission 
compared with those with lower infliximab trough levels.31 
The detection of antibodies to infliximab  correlated with a 
shorter duration of response and a higher rate of infusion reac-
tions for Crohn’s disease patients receiving infliximab.7 Data 
from adalimumab trials are more conflicting. The CLASSIC I 
and CLASSIC II  trials were  analyzed to explore a possible 
correlation between adalimumab trough levels and clinical 
remission.32 Mean adalimumab trough levels were higher 
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in patients who achieved clinical remission at week 4 in the 
CLASSIC I trial compared with patients without clinical remis-
sion (8.10 versus 5.05 µg/mL; P,0.05). However, the vari-
ability in adalimumab concentrations was high in this study, 
and no cutoff concentration that predicted remission could 
be identified. A single-center cohort from Leuven of Crohn’s 
disease patients receiving adalimumab treatment after inflix-
imab failure showed lower mean trough levels (3.2 µg/mL) for 
patients who discontinued therapy compared with for patients 
who were able to continue therapy beyond 24 weeks.9
How trough levels and antibodies to infliximab can guide 
optimization of infliximab therapy was outlined in a study by 
Afif et al.33 This study showed that measurement of trough 
levels and antibodies to infliximab affected therapeutic man-
agement in 73% of tests. In the case of low or undetectable 
infliximab trough levels, dose escalation was successful in 
86% of patients. In patients who developed antibodies to 
infliximab, 92% responded favorably to a switch in therapy, 
whereas only 17% showed benefit from infliximab dose 
escalation.33 Comparable studies that focus on optimization 
of adalimumab therapy are lacking, although it is likely that 
similar algorithms can be used in clinical practice.
Adjustment of therapy  
after secondary nonresponse
The preferred strategy in secondary nonresponders to 
 adalimumab is the optimization of therapy before switching 
to alternative anti-inflammatory agents. First, the approved 
options for alternative biological therapy for Crohn’s disease 
are limited, and most patients might already have failed 
in fliximab before starting adalimumab. Second, switching to 
an alternative anti-TNF agent is generally associated with a 
reduced response rate when compared with anti-TNF-naïve 
patients.
In the case of secondary nonresponse accompanied 
by low or undetectable trough levels, adherence to adali-
mumab therapy should be evaluated. Nonadherence can 
have various causes, including adverse events and beliefs 
about medication. Overall adherence to adalimumab for 
Crohn’s disease is calculated at 83%.34 Improving adherence 
is a cost-effective intervention and should be used when 
appropriate.
Adalimumab dose escalation is a frequently used strategy 
to regain clinical response. This strategy can be employed 
empirically in the case of increasing symptoms at the end 
of an injection cycle or if laboratory support for measuring 
trough levels and antibodies to adalimumab is not available. 
However, measurement of trough levels and antidrug 
 antibodies, if available, is recommended because limited 
benefit from dose escalation can be expected if trough levels 
are in a therapeutic range or if high titers of antibodies to 
adalimumab are present.
Following an empirical strategy, dose escalation was 

























Figure 1 Suggested algorithm for the management of loss of response to adalimumab in Crohn’s disease patients.
Abbreviations: CD, Crohn’s disease; ADA, adalimumab; iBS, irritable bowel syndrome.
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end of follow-up.12,35 A systematic review calculated that 
37% of primary responders require dose intensification for 
loss of response, whereas the annual risk for adalimumab dose 
escalation is approximately 25%.36 The latter review also cal-
culated the rate of regaining clinical response after dose escala-
tion; this percentage was 71.4%. In a single-center cohort from 
Leuven, 60% of initial responders to adalimumab required 
dose escalation during a median follow-up of 20 months, 
which provided clinical benefit in 75.7% of  participants.9 This 
study also nicely illustrated that dose escalation from 40 mg 
eow to 40 mg weekly increased mean trough levels from 4.8 
to 9.4 µg/mL. This increase in trough level correlated well 
with clinical response. Responders  displayed an increase in 
median trough levels of 5.9 µg/mL compared with 0.0 µg/mL 
for nonresponders to dose escalation.9  Collectively, these data 
show that adalimumab dose escalation is a successful strategy 
to regain clinical response that at least in part is mediated 
through optimization of trough levels. Of note, a nationwide 
retrospective Belgian study evaluated the effect of subsequent 
dose de-escalation to 40 mg eow. This strategy was attempted 
in 54% and was successful in 63% of participants.37
Surprisingly, rates of clinical remission were similar 
between subjects with a detectable trough level and those 
with an undetectable trough level at weeks 24 and 56 of the 
CLASSIC II trial.32 Indeed, a similar observation was made 
in the SONIC trial: The steroid-free remission rate among 
subjects without detectable infliximab trough levels was 
relatively high (59%).31 It is possible that peak adalimumab 
concentrations in patients who maintain clinical remission 
despite undetectable trough levels is sufficient to maintain 
their clinical state. Otherwise, some patients might not be 
in need of adalimumab maintenance therapy after successful 
induction course. The latter hypothesis is supported by the 
fact that an undetectable infliximab trough level was a predic-
tor of maintenance of remission after discontinuation of anti-
TNF therapy in the Infliximab Discontinuation in Crohn’s 
Disease Patients in Stable Remission on  Combined Therapy 
with Immunosuppressors (STORI) trial.38  Adalimumab 
trough levels might have more clinical effect in the case of 
loss of response rather than continuing clinical remission.
Antibody formation to anti-TNF agents is generally 
associated with reduced efficacy, and switching to another 
anti-TNF blocker can be beneficial. In rheumatic diseases, 
immunogenicity to adalimumab is associated with lower 
trough levels and efficacy, as well as higher discontinua-
tion rates.39 In Crohn’s disease, limited data are available 
to estimate the effect of immunogenicity on adalimumab 
efficacy. The Leuven cohort described 12 patients who 
developed  antibodies to adalimumab.9 Eleven of 12 patients 
demonstrated a trough level lower than 0.094 µg/mL at least 
once during follow-up, as well as a lower median trough 
level throughout the entire follow-up period, and 11 patients 
discontinued adalimumab therapy. A small retrospective 
study (n=30) from the Netherlands found adalimumab anti-
body formation in 17% of participants, which correlated 
with nonresponse to adalimumab.40 According to available 
data, immunogenicity correlates with unfavorable outcomes 
such as lower trough levels and higher discontinuation rates. 
However, the presence of antibodies to adalimumab by itself 
might not be sufficient for a switch in therapy.
Infliximab studies demonstrated that factors such as 
antibody titers and functionality of drug antibodies in 
addition to trough levels are probably more relevant to the 
clinical outcome than the development of drug antibodies 
by itself. This is illustrated by the observation that three of 
seven subjects (week 24) and two of seven subjects (week 
56) who developed antibodies to adalimumab in the CLAS-
SIC II trial were in remission during follow-up.11 Further 
studies regarding the relevance of adalimumab antibodies 
for clinical outcome and optimization of therapy are needed 
in the near future. However, if in the case of secondary 
nonresponse to adalimumab, immunogenicity is combined 
with low to undetectable trough levels, switching to another 
anti-TNF agent is frequently required. It should be noted that 
only indirect evidence from infliximab studies is available 
to guide this decision. The reverse switch is effective, as 
shown in patients switching from infliximab to adalimumab 
because of anti-infliximab antibodies combined with low 
trough levels.33 If adalimumab was the first anti-TNF agent 
for an individual patient, infliximab is a logical alternative. 
 However, a significant percentage of patients failed inflix-
imab before starting adalimumab. Switching to a third anti-
TNF agent, certolizumab, can be of benefit. Prior primary 
nonresponse to anti-TNF therapy and persistent disease 
activity after 3 months of therapy with the third anti-TNF 
agent predict decreased efficacy of this switch.41 In most 
countries, only infliximab and adalimumab are approved for 
the treatment of Crohn’s disease, and the lack of approval by 
regulating authorities often does not allow for a switch to a 
third anti-TNF agent.
Recent data suggest that infliximab retreatment is feasible 
in this case. In a series of 29 patients failing adalimumab after 
prior infliximab use who subsequently restarted infliximab, 
93% experienced sustained clinical benefit after 3 months.42 
After 18 months, 62% continued infliximab treatment. Two 
patients experienced anaphylactic reactions.
If adalimumab trough levels are within a therapeutic 
window, it is questionable whether dose escalation will 
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provide clinical benefit in secondary nonresponders.15,43 
Anti-TNF therapy in this scenario is not able to control 
intestinal inflammation, possibly because of a switch in the 
mechanism of inflammation.44 As a consequence, a switch to 
an alternative anti-TNF agent is less likely to result in clinical 
benefit. A study from the Mayo Clinic evaluated all Crohn’s 
disease patients who underwent measurement of infliximab 
drug levels and antibodies to infliximab.33 Fifty-one patients 
demonstrated therapeutic infliximab trough levels, 62% had 
no evidence of active inflammation, and for the remaining 
38%, various strategies were followed, including infliximab 
continuation, surgery, switch to another anti-TNF agent, and 
the addition of immunosuppressive treatment.  Unfortunately, 
no well-designed studies have addressed the issue of active 
inflammation, despite therapeutic adalimumab drug lev-
els, but most clinicians would not anticipate benefit from 
adalimumab dose escalation. In these particular situations, 
switching to an alternative drug class is recommended. In the 
management of rheumatoid arthritis, switching between drug 
classes is a well-accepted and effective strategy. For example, 
switching to rituximab (anti-CD20 monoclonal) or abatacept 
(anti-CD80/anti-CD86 fusion protein) after anti-TNF failure 
is used by rheumatologists in clinical practice.45,46 Alternative 
therapies after anti-TNF failure for Crohn’s disease include 
natalizumab, an antibody to α4 integrin,19 or agents that 
await approval by regulating authorities, such as ustekinumab 
(anti-IL12/IL23)47 or vedolizumab (anti-α4β7 antibody).20 
Finally, clinical trials can be considered, but up to 70% of 
inflammatory bowel disease patients meet exclusion criteria 
and become ineligible for participation.48
Concomitant immunosuppression is thought to increase 
the efficacy of anti-TNF therapy. Crohn’s disease patients 
in the SONIC trial who were naïve to immunomodula-
tors or anti-TNF therapy achieved higher rates of clinical 
remission when receiving combination therapy rather than 
monotherapy.31 However, both the CLASSIC II trial and the 
CHARM trial did not show differences regarding  adalimumab 
levels and remission rates in patients with or without con-
comitant immunosuppression.12,32 Similarly, the Leuven adali-
mumab cohort did not show differences in remission rates, 
 adalimumab trough levels, or immunogenicity when stratified 
for concomitant immunosuppression.9 Finally, when assessed 
per semester of maintenance therapy, combination therapy 
with adalimumab and immunosuppressive therapy did not 
result in a reduction in semesters with flares compared with 
adalimumab monotherapy.49 So far, data are lacking to sup-
port the concept that concomitant immunosuppression will 
improve therapeutic efficacy of adalimumab therapy.
Some patients will not qualify for or do not respond to 
the therapeutic options of adalimumab dose escalation or 
 switching within or to another drug class. In these individual 
cases, surgical intervention should be  considered. In specific 
cases such as patients with small areas of  inflammation, 
a limited resection can be preferred over continuing 
medical treatment. However, this approach is dependent on 
individual surgical history, comorbidity, age, and patient 
preference.
Summary and conclusion
The majority of Crohn’s disease patients will show initial 
clinical benefit from adalimumab treatment, but failure 
resulting from nonresponse or adverse events is commonly 
observed. In the case of adalimumab failure, clinical assess-
ment is required to confirm inflammatory disease activity 
and rule out noninflammatory causes. Evaluation should 
include biomarkers (fecal calprotectin and serum CRP), 
colonoscopy, and/or magnetic resonance enterography/
enteroclysis. Furthermore, adalimumab trough levels and 
antibodies to adalimumab should be evaluated in these 
situations. In the case of low or undetectable adalimumab 
trough levels, dose escalation to 40 mg weekly is recom-
mended, whereas high antibody titers or adverse events fre-
quently result in switching to an alternative anti-TNF agent 
such as infliximab. Active inflammation despite therapeutic 
adalimumab trough levels requires alternative strategies 
such as switching to drugs with a different mode of action 
or surgical intervention.
One area of future research includes the use of trough 
levels and antibody formation to affect optimization of adali-
mumab treatment. Hence, well-designed prospective trials 
that focus on this particular issue are needed. Furthermore, 
novel drugs with alternative modes of action are warranted 
for Crohn’s disease patients who fail anti-TNF therapy. 
Vedolizumab (a therapeutic antibody directed against α4β7 
integrin on lymphocytes) and ustekinumab (an antibody 
that targets interleukin 12 and interleukin 23) will soon find 
their way into daily practice and will likely offer signifi-
cant therapeutic alternatives for the management of these 
patients. Rheumatoid arthritis serves as a model in which 
the  availability of drugs with distinct working mechanisms 
allows treating physicians to switch therapies if needed and, 
more important, to tailor or combine treatment strategies to 
individual characteristics. For now, optimization of adali-
mumab therapy before switching to alternative therapies in 
Crohn’s disease patients remains mandatory to fully use the 
limited therapeutic options currently available.
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